Background: The ability of inflammatory markers to predict disability in later life has received growing attention. However, the current evidence came predominantly from Caucasians and the role of genomic ancestry has not been investigated. Objective: We investigated the prognostic value of multiple citokynes and chemokines for incident disability in admixed older Brazilians and whether genomic African and Native American ancestry affects the association. Design: Population-based longitudinal study. Setting: The Bambui-Epigen (Brazil) Cohort Study of Aging. Subjects: 1,171 males and females aged 60 years over 15-year of follow-up. Methods: Outcome examined was incident activity of daily living (ADL) disability assessed annually (10,039 measures were performed). Serum levels of citokynes (IL6, IL12, TNF, IL10, and IL1β) and chemokines (CCL2, CCL5, CXCL8, CXCL9 and CXCL10) were measured at baseline. We used 370,539 Single Nucleotide Polymorphisms (SNPs) to estimate each individual genomic ancestry proportions. Potential confounding variables included a wide range of socio-demographic variables and health indicators. Statistical analyses were based on competing risk framework. Results: The incidence rate of disability was 57.9 per 1,000 person-years. IL6 level at the highest quartile showed an independent association with ADL disability (SRH = 1.32; 95% CI: 1.03, 1.70). Other inflammatory markers showed no statistically significant associations with the outcome. Neither genomic African nor Native American ancestry had an effect modifier on the associations (P for interaction >0.05 for all). Conclusion: Among multi-inflammatory markers, only IL6 had the potential to identify people at increased risk of ADL disability, independently of ethno-racial background.
Inflammatory markers have been postulated as a tool to identify people at increased risk of disability.
The role of genome-based ancestry on the ability of inflammatory markers to predict disability is unknown.
We examined whether genome African and Native American ancestries affect the association between inflammatory markers and incident disability in a large cohort of older Brazilian adults.
Elevated levels of Interleukin-6 were associated with increased risk of disability, independently of genome-based ethno-racial background.
Interleukin-6 may be a useful tool for timely prevention of disability in a highly admixed older population.
Introduction
Disability in later life is a public health concern worldwide due to increase in demand and cost of long-term care [1] . Identifying predictors of disability can potentially contribute not only to a better understanding of underlying mechanisms, but also to targeting vulnerable groups for timely prevention. Given that there is evidence linking inflammation to the process of ageing and age-related diseases, the ability of inflammatory markers to predict disability in old age has received growing attention [2] .
Cytokines and chemokines are important players in the immune responses [2] . There is considerable evidence showing that elevated baseline levels of Interleukin-6 (IL6), a proinflammatory cytokine, has a prognostic value for activities of daily living (ADL) disability or impairment in mobility [3] [4] [5] , muscle strength loss [6] [7] [8] [9] [10] and sarcopenia [11] in short and medium terms (up to 5 years). The prognostic value of IL6 for long-term physical functioning is unknown. In the MacArthur Studies of Sucessful Aging, baseline IL6 level did not predict physical functioning performance 7 years later [12] . Studies examining the prognostic value of other cytokines and chemokines for physical functioning are still scarse and have reported inconsistent results [4, 7, 5] .
The above mentioned evidence came predominantly from Caucasians [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . To the best of our knowledge, no previous study has specifically examined the influence of genetic ancestry on those associations. Brazil, the largest Latin American country, offers a valuable opportunity to explore this issue. The Brazilian population originates from African, European and Native American ancestral roots [13] . The absence of legal segregation and other factors contributed to an emergence of a highly admixed population [14] .
We used 15-year follow-up data from the Bambui-Epigen study [15] , the longest running cohort study of aging in Brazil, with two main objectives: (1) to examine the association between multiple inflammatory markers and long term ADL disability; and (2) to investiagate whether genomic African and Native American ancestry levels affects the ability of those biomarkers to predict the outcome.
Methods

Study Population
The Bambui cohort study of aging is ongoing in Bambuí, a city of approximately 15,000 inhabitants in Southeast Brazil. From an ethno-racial perspective, the cohort population consists of an admixture of African (10%), Native American (5%), and European (85%) genomic ancestries, in similar proportions to that estimated for the Brazilian population, excluding the Amazon region [14] . Detailed information on this cohort can be found elsewhere [15] . Briefly, the population eligible for the cohort consisted of all residents aged 60 years and older on the 1st of January 1997 (92% of the 1,742 inhabitants in this age group participated).
Annually, from 1997 to 2011, cohort members underwent subsequent annual follow-up by face-to-face interview. Blood collection and other procedures for the current analysis where performed at the baseline survey. Deaths occurring from study enrollment to December 31, 2011, were considered in this analysis. Deaths were reported by next of kin during the annual follow-up interview and were ascertained through the Brazilian mortality information system. Death certificates were obtained for 95.5% of all deceased participants. Cohort members with an ADL disability at baseline (n = 171) were excluded from the current analysis (see bellow).
Activity of daily living disability
Annually, from 1997 to 2011, physical functioning was measured as self-reported limitations in the following basic ADL: dressing, walking across a room, bathing or showering, eating, getting in or out of bed, using the toilet. The questions had four possible answers: no difficulty, some difficulty, great difficulty and unable to perform. Onset of disability was considered when a participant reported, for the first time, great difficulty or unability to perform one or more tasks.
Inflammatory markers (cytokines and chemokines)
Blood samples for measurement of cytokines and chemokines were collected at the baseline survey in early morning. The Cytometric bread array assay (CBA immunoassay kit; Becton was used for sample analysis. The coefficients of variation intra and inter-assays were 5-10% and 7-12%, respectively. Based on their distributions, IL6, CXCL8, CCL2, CXCL9, CCL5 and CXCL10 were log-transformed and considered as continuous variables in our analysis. IL1β, IL10, IL-12 and TNF showed very low detectable levels and were considered as dichotomous variables.
Genetic and ancestry analyses
Cohort participants were genotyped with the Omni 2.5M array (Illumina, California) [13] .
Ancestry inference was performed by using the model-based method [16] . We used 370,539
SNPs to estimate each individual African, European and Native American tri-hybrid ancestry proportions, based on public datasets parental populations. We used the matrix of kinship coefficients and a network-based approach to identify families, and identified them as categorical variables for the association tests described below. Pairs of individuals were considered as related if they had a kinship coefficient >0.1 (first and second-degree relatives).
Further details are described elsewhere [13] .
Covariates
Covariates comprised baseline socio-demographic characteristics (age, sex, education and household income), lifestyle (smoking, alcohol consumption and physical activity), body mass index and health conditions. We categorized schooling into <4 years, 4-7 and 8 years.
Monthly household income per capita was divided into tertiles (<USD 90.00 is the lowest tertile). Current smokers were participants who had smoked at least 100 cigarettes during their lifetime and who still smoke. Leisure-time physical activity was defined as activity of any intensity for 20-30 minutes in the previous 3 months, and categorized into at 3 times a week, <3 times a week and never. Alcohol consumption was defined by consumption of 14 doses per week in previous 12 months. Body mass index was categorized into <18.5, 18.6-24.9 and 24 kg/m 2 . Health conditions considered were: hypertension (systolic blood pressure 140 mmHg or diastolic blood pressure 90 mmHg and/or treatment); diabetes (fasting blood glucose 126 mg/dL and/or treatment); arthritis (previous medical diagnosis of any joint condition); coronary heart disease (medical diagnosis of myocardial infartion or angina pectoris as assessed by the Rose's questionnaire); intermitent claudication (Rose's questionnaire), stroke (medical diagnosis), fasting high non-HDL cholesterol (130 mg/dL); heart failure (plasma B-type natriuretic peptide level >100 pg/mL); anaemia (hemoglobin <13g/dL for men and <12g/dL for women), depressive symptoms (defined by a 12-item version of the General Health Questionnaire score 5 [17] ); cognitive impairment (defined by a Mini-Mental State Examination score <22 -below the 25th percentile-or by the need for a proxy interview-87 participants). Based on the above mentioned health conditions (all as dichotomous variables)
we used principal component analysis [18] to create a morbidity score that ranged from - to + (higher scores indicated worse health). Scores were divided into quartiles.
Statistical analysis
We used competing-risks regression [19] to estimate the multivariate subhazard ratios (SHR) to model 15-year survival-time disability data. In order to consider death that could be related to disability, we used the date of death as a competing risk event. All regression models using genomic measures included a clustered (family) robust variance term to avoid potential bias resulting from analysis of individuals who were related (807 participants were first-and second-degree relatives).
First, we examined the association between inflammatory markers with incident ADL disabilit, by estimating sub hazard ratios (SRH) adjusted for socio-demographic, lifestyle, body mass index and health conditions (morbidity score). Then we added genomic ancestry variables to the previous models. Furthermore, we examined separately the statistical significance of multiplicative interactions between the inflammatory marker and genomic African and Native
American ancestry on the outcome, controlling for all the above mentioned covariates. A statistically significant association was defined by a P value <0.05 in the log-likelihood test.
An additional analysis was performed to examine the association between baseline quartiles of IL6 serum levels and incident ADL disability. In this analysis we also examined the possibility of reverse causation by excluding those participants whose disability onsets occurred within 12 months. Furhter, we implemented fully adjusted competing-risks regression models to estimate cumulative incidence rates for disability by year, according with baseline IL6 levels in quartiles and plotted the results. Because we did not have enough power to stratify the analysis by gender, men and women were pooled and sex was considered as a covariate in our analyses. Statistical analyses were conducted using STATA 14.2 statistical software (Stata Corporation, Texas).
Results
Our analysis was based on 1,171 participants who had no ADL disability at baseline and had complete information for all other study variables. During the study period, 383 cohort participants died, 581 evolved to disability and 104 were lost to follow-up. Along the 15-year follow-up, 10,039 measures of ADL were made. The incidence rate of disability was 57.9 per 1,000 person-years. The mean age was 68.6 years (range 60 to 95) and 61.0% were women.
Other baseline characteristics of study participants are shown in Table 1 . As shown in Table 2 , IL6 baseline serum level showed a positive statistically significant association with ADL disability in a model adjusted for socio-demographic, lifestyle, body mass index and morbidity score (SHR = 1.07; 95%CI: 1.01-1.13). Further adjustments for genomic African and Native American ancestry had no impact on the above mentioned estimates. Other biomarkers showed no statistically significant association with the outcome.
Additionally, we found no evidence of statistically significant interactions affecting the ability of any biomarker to predict ADL disability neither for African nor for Native American ancestry (P for interaction >0.05 for all). (Table 3) . Again, the addition of genomic ancestry variables to the previous models had no impact on the predictive value of IL6 levels for ADL disability. The exclusion of onsets prior to 12 months slightly increased the SHR values, and the graded nature of the association became more evident with SRH (95% CI) equal to 1.33 (0.98-1.81), 1.40 (1.04-1.88) and 1.48 (1.09-2.01) for those at the 2 nd , 3 rd and the highest relative to the lowest quartile. Figure 1 shows the cumulative probability of ADL disability by year, according with quartiles of baseline IL6. The clearly separated lines between the highest and the lowest quartile support the associaton between the biomarker level and the risk of ADL disability showed in Table 3 . Estimated by competing risk regression, and adjusted for socio-demographic, lifestyle, body mass index, morbidity score and genomic African and Native ancestry (continuous) and cluster in family.
Dicussion
Our major finding is that elevated IL6 serum levels predicted very long term incident ADL disability. The observed association persisted after careful controlling for a wide range of covariates, and suggests graded effect. Because this association remained after excluding onsets prior to 12 months, it appears not to be explained by reverse causation, that is, a situation in which the outcome precedes and causes the exposure instead of the other way around [20] .
Notably, the individual proportion of genomic African and Native American ancestry did not affect the predictive value of this biomarker for the outcome.
The association between IL6 levels with ADL disability is in agreement with a number of previous studies conducted in the USA and Europe [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . Two novel findings are that (i) IL6 predicts ADL disability in very long term in an admixed population and that (ii) ancestry background does not play a role on this association. Another issue is the cut off value of the marker. IL6 cut offs of 2.50 pg/mL [3] , 2.98 pg/mL [5] and 3.1 or 3.8 pg/mL [10] have been proposed to discriminate persons at risk and those not at risk for disability. Our results showed that persons with IL6 level higher than 2.2 pg/mL were at increased risk.
The exact mechanism linking increased IL6 level to disability is unclear. The catabolic effect of IL6 on muscle has been postulated [6, 7, 11] . However, because IL6 is associated with increased risk of chronic diseases that, in turn, predispose to disability, there is a debate about whether IL6 is a direct cause of physical decline or simply sumarize the burden of illness in older adults [2] . Our results indicate that IL6 predicts ADL disability, independently of several health and health-related measures, but we were not able to capture changes over time.
Therefore, the key issue is to disentangle the complex pathway linking IL6 to disability, which was not possible in our analysis.
There are only few studies examining the association between other cytokines and chemokines with physical decline. Two earlier reports, involving around 2,000 participants from the Health, Aging and Body Composition studies showed an association between baseline TNFα with 30-months incident mobility limitation [4] and with a 5-year decline in grip strenght in men (but not in women) [7] . A more recent study, involving 303 participants of the Belfrail Study in Belgium, examined the association between a large battery of cytokines and chemokines with 1.66-year global functioning decline. Except for IL6, no other biomarker had the potential to identify persons at increased risk [5] . Our results, based on a larger number of participants and a longer follow-up period, is in agreement with the latter, that is, among a large battery of cytokines and chemokines, only IL6 was found to be statistically significantly associated with incident ADL disability.
Strengths of the present study include its well-defined community-based sample followed for a long period. Our study also incorporated a robust set of health and health-related measures that could confound the association between the inflammatory markers and onset of disability.
Another important strength was the use of genome measures of ancestry, instead of ethno-racial self-classification, which is prone to misclassification, particularly in admixed populations [14] . A limitation in this analysis is inherent to longitudinal studies of ageing. Older adults are at increased risk of death, which in turn might lead to differential censoring. As an attempt to overcome this limitation, we used competing risk framework in our analysis, considering the data of death as informative censoring. In our initial exploratory analysis of the association between multiple citokynes and chemokines with the outcome, we did not adjust for multiple testing -which could lead to false positive results. However, the association between IL-6 with incident ADL disability was confirmed in subsequent analysis based on the quartile distribution of the biomarker level and, also, in an analysis restrict to onsets after 2 years. Therefore, it is unlekly that those are false positive results. In addition, changes over time in exposure status and ADL trajectories were not investigated. This limitation, however, do not preclude our conclusion that, despite eventual unmeasured changes over time, baseline elevated level of IL6 is an independent predictor for very long-term ADL disability.
In summary, our findings showed that in a cohort of admixed older Brazilian adults, only IL6 has the potential to identify persons at increased risk of future ADL disability, independently of ethnoracial background.
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